01Identity
What is it?
The finished gel contains a specific HA profile with product-dependent cross-linker, residual limits, excipients and sometimes lidocaine; formulations are not equivalent.
Hyaluronic Acid Fillers · Aesthetic Medicine · Istanbul
Hyaluronic Acid Fillers · Aesthetic Medicine · Istanbul
Hyaluronic Acid Fillers
Hyaluronic acid identifies a material family, not one filler. Concentration, molecular profile, cross-linking, particle or gel structure, rheology, excipients, lidocaine, approved area and intended tissue influence behaviour and risk.
Vascular occlusion can cause skin necrosis, visual impairment, blindness or stroke. The possibility of using hyaluronidase does not make every filler outcome or tissue injury completely reversible.
Quick Orientation
Identity · composition · preparation · route
The treatment name is only the start of the medical description.
A responsible discussion identifies the exact preparation or device, how it was made, where it is intended to act and which clinical question is being assessed.
02Production
How is it prepared?
HA source, purification, cross-linking chemistry, gel sizing, sterilisation, prefilled syringe, storage and batch release define the product.
03Route
How does it reach tissue?
The gel is implanted into a product- and indication-specific tissue plane. Intravascular placement or compression can interrupt blood flow.
04Target
What is the clinical target?
Volume, contour, fold support or another labelled anatomical aim is distinguished from skin hydration, muscle treatment and surgical lifting.
Method Boundary
A family of prescription-use gel implants
Product type, cross-linking, rheology and anatomical target stay connected.
The intended role, product identity and target tissue stay visible so unlike procedures are not presented as one interchangeable class.
What may be considered
- Evaluate one labelled gel for one defined anatomical aim
- Match rheology and tissue behaviour to the clinical target
- Document baseline asymmetry and previous filler
- Prepare a product-specific complication and follow-up pathway
What must not be inferred
- Treat every HA gel as interchangeable or fully reversible
- Use one product evidence base for every facial or body region
- Replace diagnosis of a lump, swelling or prior filler problem
- Guarantee symmetry, natural appearance, duration or no complications
The precise product, treated area, tissue plane and vascular-risk plan must be clear; hyaluronic acid alone is not an adequate treatment description.
Medical Suitability
Clinical question before method selection
Five checks precede any personal decision.
Anatomy, facial movement, tissue thickness, previous filler, asymmetry, dental or inflammatory history and the exact gel are reviewed together.
- 01
Define the anatomical aim
Volume loss, contour, fold, asymmetry and skin-quality concerns are separated before a filler is considered.
- 02
Map tissue and vessels
Vascular pathways, tissue thickness, previous surgery, scars and high-risk regions are assessed in person.
- 03
Audit previous filler
Product, date, region, persistent material, nodules, swelling and prior complications may alter or prevent treatment.
- 04
Verify the new gel
Composition, cross-linking, rheology, labelled indication, syringe, batch and storage are checked.
- 05
Review personal risk
Allergy history, infection, autoimmune or inflammatory conditions, medicines, pregnancy and breastfeeding require assessment.
Product and Treatment Path
Traceability without a public injection recipe
Gel behaviour and anatomical target must agree.
A product selected for one labelled area or tissue role cannot be transferred casually to another region. Vascular preparedness is part of planning.
01Product
Gel identity and rheology
The exact syringe is reviewed for HA profile, cross-linking, excipients, labelled use and tissue behaviour.
- Verify product and batch
- Record cross-linking and rheology
- Check labelled region and indication
02Anatomy
Target plane and vascular risk
The region, tissue plane and nearby vessels are assessed without publishing an injection path.
- Map anatomy in person
- Review previous filler and surgery
- Prepare a time-critical response route
03Review
Traceability and endpoint
The product, region and observations remain linked to early circulation checks and later contour review.
- Retain syringe and batch details
- Document baseline and immediate findings
- Set safety and endpoint reviews
No product choice, volume, dilution, needle/cannula, entry point, anatomical path, injection plane or management protocol is provided publicly.
Evidence and Limits
Read the data at product and indication level
Every filler approval is product-, area- and endpoint-specific.
Trials for lips, cheeks, chin, folds, under-eye hollows or other regions use different gels and anatomical endpoints. Results do not establish a class effect.
Match product and area
Evidence for one gel in one labelled region does not validate another gel or anatomical site.
Read rheology clinically
Laboratory measures inform behaviour but do not predict a personal aesthetic or safety outcome by themselves.
Include delayed events
Nodules, inflammation, infection and swelling can appear weeks, months or longer after injection.
Include rare severe harm
Regulatory safety information recognises necrosis, blindness and stroke after unintended vascular injection.
Published duration is a group observation for a defined product and indication, not a personal guarantee or proof that material can always be fully removed.
Individual Plan
One indication · one traceable intervention · one review point
A filler plan is an anatomical and product decision, not a syringe package.
The clinical aim, exact gel, tissue plane, baseline asymmetry, alternatives, vascular response route and stop criteria are documented.
Record the baseline
Proportions, movement, asymmetry, tissue quality and previous filler are documented without promising correction.
Select by labelled role
Product identity and rheology are matched to a defined anatomical task, not a trend or package.
Prepare for occlusion
Recognition, local medical response and product traceability are in place before injection.
Avoid automatic top-up
Swelling must settle and the endpoint must be reviewed before any further material is considered.
Course and Follow-Up
Expected reaction · adverse effect · clinical endpoint
Swelling, circulation and final contour need separate assessments.
Immediate fullness may include product, anaesthetic and swelling. It is not the final result and does not remove the need for vascular monitoring.
- 01Treatment day
Record the gel
Product, syringe, batch, region and immediate observations remain traceable.
- 02Time-critical
Check circulation and vision
Severe pain, blanching, mottling, cool skin or visual change requires immediate medical assessment.
- 03Later safety
Review delayed inflammation
Persistent swelling, nodules, redness, tenderness or infection is assessed against the exact product.
- 04Decision
Judge the endpoint after settling
Contour and asymmetry are reviewed only after early swelling; further injection is not automatic.
Risks and Alternatives
Material, anatomy and route shape risk
Vascular occlusion is uncommon but can cause permanent harm.
Common injection reactions and delayed inflammatory events sit alongside time-critical vascular complications.
01Local
Common and local
Pain, tenderness, swelling, bruising, redness, itching, unevenness and temporary functional discomfort may occur.
02Delayed
Delayed and product-related
Nodules, granuloma, infection, open wounds, migration or inflammation may emerge later.
03Time-critical
Vascular occlusion
Ischaemia can lead to tissue loss, visual impairment or blindness, stroke and damage to underlying structures.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Sudden severe or unusual pain, blanching, mottled colour, cool skin, weakness or any visual change requires immediate local medical assessment; hyaluronidase is not a guarantee of complete reversal or recovery from injury. Alternatives may include observation, skin care, botulinum toxin for a muscle-related aim, another product class, surgery or no treatment.
Istanbul and Follow-Up
A treatment decision must remain reviewable after travel
Assessment, product records and a local safety route travel together.
International care is not reduced to a treatment day. The in-person examination, exact intervention, early review and later endpoint are connected before departure.
01Before travel
Organise the question
History, previous procedures and the specific hyaluronic acid fillers question prepare the visit without confirming suitability.
02In Istanbul
Examine in person
Anatomy, tissue, active disease, product or device status, risks and alternatives are reviewed together.
03Treatment day
Keep exact records
Product or device identity, batch where relevant, treated region, route and observations remain traceable.
04After return
Arrange review
Expected reactions, stop criteria, local medical access and the later clinical endpoint are agreed before return travel.
The Doctor Aslan Approach
Product-specific, anatomy-led and reversible in decision-making
The anatomical task and the exact gel are inseparable.
Product identity, rheology, tissue plane and vascular risk are reviewed before volume is discussed. A conservative decision may be not to add filler.
Define the tissue task
Volume, contour, fold and skin-quality aims remain separate.
Name the gel
Cross-linking, rheology, labelled area and batch remain traceable.
Respect vascular anatomy
A time-critical complication pathway is prepared before injection.
Review after swelling
No automatic top-up follows an immediate appearance.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about hyaluronic acid fillers; no personal protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Hyaluronic Acid Fillers?+
Hyaluronic Acid Fillers is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Hyaluronic Acid Fillers?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Define the anatomy · verify the gel · prepare the safety route